514 episodes
Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema
11/16/2026 | 9 mins.President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program.Jefferies 2026: Nektar Therapeutics has Rezpeg moving full speed ahead in atopic dermatitis and alopecia (and beyond) - the Head of R&D shares learnings about its mechanism
11/16/2026 | 11 mins.Jonathan Zalevsky describes how learnings from the phase 2 AD trial have helped with the study design of three phase 3 studies - and the latest on alopecia. He emphasizes how the company seems to be seeing a deepening of responses from this Treg targeting mechanism over time.Jefferies 2026: Sofinnova Partners announced today a new $815M fund today that will invest in mostly later stage European companies
11/16/2026 | 10 mins.Managing Partner Graziano Seghezzi tells us about the new fund and what it will invest in, and comments on the environment for European biotech today.Jefferies London: While its in the middle of the closely watched Attruby launch, BridgeBio has two other medicines in front of FDA and another big phase 3 readout scheduled for later next year
11/16/2026 | 9 mins.Founder & CEO Neil Kumar shares his take on how the Attruby launch is going, and also talks Limb-girdle muscular dystrophy type 2I/R9, achondroplasia, and hypoparathyroidism.STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors
11/12/2026 | 8 mins.Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China.
Listen to BiotechTV - News, The Quanta Podcast and many other podcasts from around the world with the radio.net app

Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features














